Biotech Values

[jb_118]

Correct. There was only a single voting question that asked if they had demonstrated both efficacy and safety in preventing adverse CV outcomes.

It did not specify a population, age, comorbidities etc etc. Hence the 16-0 vote. Then each voting member elaborated on their vote and their views of primary vs secondary prevention. I was surprised a bit by having only one vote, but it gives the FDA a nominal unanimous 'approval' to do what they want I guess.